Abstract
Maintenance therapy with pemetrexed is well tolerated and achieves prolonged progression-free and overall survival in patients with advanced lung adenocarcinoma. The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) is a recently identified fusion oncogene that exists in ~5% of non-small-cell lung cancers (NSCLCs). It was demonstrated that ALK-positive NSCLCs exhibit a high response rate to the ALK inhibitor crizotinib. This is the case report of a patient with NSCLC harboring EML4-ALK rearrangement, who experienced slowly progressive disease within 4 years of maintenance treatment with pemetrexed and later exhibited a marked response to crizotinib. The sustained clinical benefits suggest further investigations on anticancer agent administration.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.